AbbVie Inc.
Therapeutic DLL4 Binding Proteins

Last updated:

Abstract:

DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.

Status:
Application
Type:

Utility

Filling date:

7 Feb 2020

Issue date:

14 Jan 2021